Journal of Periodontal and Implant Science

Korean Academy of Periodontology (대한치주과학회)
권호 표지
DOI QR코드

DOI QR Code

Implant failure associated with oral bisphosphonate-related osteonecrosis of the jaw

  • Shin, Eun-Young (Department of Periodontology, Kyung Hee University School of Dentistry) ;
  • Kwon, Young-Hyuk (Department of Periodontology, Kyung Hee University School of Dentistry) ;
  • Herr, Yeek (Department of Periodontology, Kyung Hee University School of Dentistry) ;
  • Shin, Seung-Il (Department of Periodontology, Kyung Hee University School of Dentistry) ;
  • Chung, Jong-Hyuk (Department of Periodontology, Kyung Hee University School of Dentistry)
  • Received : 2009.12.24
  • Accepted : 2010.03.09
  • Published : 2010.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The aim of this study is to report a case of oral bisphosphonate-related osteonecrosis of the jaw (BRONJ) resulting in implant failure. Methods: A patient suspected of having BRONJ was referred to the Department of Periodontology, Kyung Hee University School of Dentistry for the evaluation and treatment of exposed bone around implants. Results: The patient, who had been taking oral bisphosphonates (BPs) for about a year, was successfully treated with systemic antibiotics, chlorhexidine mouth rinse, explantation, and surgical debridement of necrotic bone. Conclusions: The results of this case suggest that a patient taking BPs orally should be treated cautiously. Appropriate management including cessation of BPs and respective dental treatment may reduce the development of BRONJ.

Keywords

References

  1. Wang HL, Weber D, McCauley LK. Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report. J Periodontol 2007;78:584-94. https://doi.org/10.1902/jop.2007.060239
  2. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34. https://doi.org/10.1016/j.joms.2004.02.004
  3. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. https://doi.org/10.1016/S0278-2391(03)00720-1
  4. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76. https://doi.org/10.1016/j.joms.2006.11.003
  5. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006;137:1144-50.
  6. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw: 2009 update. J Oral Maxillofac Surg 2009;67:2-12.
  7. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-52. https://doi.org/10.1200/JCO.2005.04.2465
  8. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melako-poulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7. https://doi.org/10.1200/JCO.2005.02.8670
  9. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-410. https://doi.org/10.1016/j.joms.2007.08.003
  10. Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000;66:100-3. https://doi.org/10.1007/PL00005830
  11. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005;136:1658-68.
  12. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99. https://doi.org/10.1056/NEJMoa030897
  13. Bagan JV, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis JM, et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 2006;42:327-9. https://doi.org/10.1016/j.oraloncology.2005.08.001
  14. Kademani D, Koka S, Lacy MQ, Rajkumar SV. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 2006;81:1100-3. https://doi.org/10.4065/81.8.1100
  15. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61. https://doi.org/10.7326/0003-4819-144-10-200605160-00009
  16. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75. https://doi.org/10.1016/j.joms.2005.07.010
  17. Jeffcoat MK. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants 2006;21:349-53.
  18. Madrid C, Sanz M. What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. Clin Oral Implants Res 2009;20 Suppl4:87-95.
  19. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates: the experience of the National Cancer Institute of Milan. Ann Oncol 2009;20:137-45.
  20. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009;20:117-20.

Cited by

  1. Epidemiological aspects of rheumatoid arthritis patients affected by oral bisphosphonate-related osteonecrosis of the jaws vol.8, pp.None, 2010, https://doi.org/10.1186/1746-160x-8-5
  2. Periodontal management in Paget's disease: Case presentation and a brief review of literature vol.16, pp.1, 2010, https://doi.org/10.4103/0972-124x.94622
  3. Osseointegration of Dental Implants and Osteonecrosis of the Jaw in Patients Treated With Bisphosphonate Therapy: A Systematic Review vol.39, pp.4, 2013, https://doi.org/10.1563/aaid-joi-d-11-00234
  4. Osteopathology induced by bisphosphonates and dental implants: clinical observations vol.17, pp.1, 2010, https://doi.org/10.1007/s00784-012-0708-2
  5. Incidence of bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients taking bisphosphonates for osteoporosis treatment-a grossly underestimated risk? vol.17, pp.8, 2010, https://doi.org/10.1007/s00784-012-0873-3
  6. Alendronate-associated osteonecrosis of the jaws: A review of the main topics vol.19, pp.2, 2010, https://doi.org/10.4317/medoral.19094
  7. What is the impact of bisphosphonate therapy upon dental implant survival? A systematic review and meta‐analysis vol.27, pp.2, 2010, https://doi.org/10.1111/clr.12526
  8. Dental Implant Placement in Patients on Bisphosphonate Therapy: a Systematic Review vol.9, pp.3, 2018, https://doi.org/10.5037/jomr.2018.9302